CS
APGE icon

Credit Suisse’s Apogee Therapeutics APGE Stock Holding History

Credit Suisse’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.18M Buy
17,686
+2,949
+20% +$129K ﹤0.01% 2168
2023
Q4 		$412K Buy
+14,737
New +$295K ﹤0.01% 2812

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Credit Suisse's APGE Position: Q1 2024 in Review

Credit Suisse increased its Apogee Therapeutics (APGE) stake by 20% in Q1 2024, buying an estimated $129K and bringing the position to 17,686 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2168.

Credit Suisse first reported a position in APGE in Q4 2023 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold APGE as of Q1 2024.

  • Credit Suisse held 17,686 shares of Apogee Therapeutics worth $1.18M as of Q1 2024.
  • Credit Suisse bought 2,949 Apogee Therapeutics shares in Q1 2024, an estimated $129K.
  • Apogee Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2168 holding.
  • Credit Suisse first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.